Skip to main content

Table 1 Binding affinity and neutralization potency characterization of the selected NAbs

From: Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants

Antigen specific mAb SARS-CoV-2 SARS-CoV
RBD KD (nM) Receptor blocking IC50 (ng/ml) Pesudo virus IC50 (ng/ml) Authentic virus IC50 (ng/ml) RBD KD (nM) Receptor blocking IC50 (μg/ml) Pesudo virus IC50 (μg/ml)
SARS-CoV-2 specific 24-2K 6.1 63.4 17.0 171.0 N.D. N.D. N.D.
24-1L 7.3 7.0 5.1 229.0 N.D. N.D. N.D.
24-11K 2.7 2.0 5.6 74.0 N.D. N.D. N.D.
24-12K 2.2 7.0 8.2 162.0 N.D. N.D. N.D.
25-C4 1.2 43.2 50.0 112.0 N.D. N.D. N.D.
25-C5 1.0 49.0 33.0 419.0 N.D. N.D. N.D.
25-C8 2.8 68.6 68.0 345.0 N.D. N.D. N.D.
25-C9 2.2 138.9 8.0 146.0 N.D. N.D. N.D.
25-B5 3.5 2.0 1.0 91.0 N.D. N.D. N.D.
25-F8 4.0 79.9 8.7 345.0 N.D. N.D. N.D.
25-G7 0.5 29.0 10.6 55.0 N.D. N.D. N.D.
26-40K 6.8 2.2 4.2 21.0 N.D. N.D. N.D.
26-34L 15.9 7.0 10.0 171.0 N.D. N.D. N.D.
26-45K 3.9 3.7 2.7 162.0 N.D. N.D. N.D.
28-15L 2.7 7.0 35.0 171.0 N.D. N.D. N.D.
28-8L 11.9 4.1 4.0 38.0 N.D. N.D. N.D.
CB6 10.7 7.0 9.7 73.0 N.D. N.D. N.D.
Crossing 25-D9 0.4 356.1 14.0 345.0 7.2 2.2 0.9
25-F7 1.2 26.5 22.0 1883.0 4.9 5.3 5.0
28-26K 0.1 89.3 25.0 330.0 4.9 3.8 3.5
CR3022 57.8 >15000 >25000 N.D. 0.9 1.9 0.4
S309 <1E-3 >15000 60.2 N.D. <1E−3 >15 0.03
  1. N.D., not determined; CB6, CR3022, and S309 were used as control [36, 38, 39]